Takeda Pharmaceutical Co Ltd - Q3 FY2023 Summary
Business Context and Reporting Period
This Form 6-K reports Takeda Pharmaceutical Company Limited's Quarterly Securities Report for the nine-month period ended December 31, 2023 (the third quarter of the 147th Business Term). The filing was submitted to the U.S. SEC on February 2, 2024. Takeda operates as a global biopharmaceutical company with key business areas in Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT) Immunology, Oncology, and Neuroscience.
Key Financial Metrics
| Metric (Nine Months Ended Dec 31, 2023) | Value (JPY Billion) | Change vs Prior Year (AER) |
|---|---|---|
| Revenue | 3,212.9 | +4.6% |
| Operating Profit | 224.1 | -44.2% |
| Profit Before Tax | 100.3 | -69.3% |
| Net Profit | 147.2 | -48.5% |
| Net Profit Attributable to Owners | 147.1 | -48.6% |
| Basic EPS | 94.10 JPY | -48.9% |
| Core Operating Profit | 865.6 | -9.3% |
| Net Cash from Operating Activities | 437.8 | -35.9% |
| Cash and Cash Equivalents (End of Period) | 288.4 | -58.0% |
| Total Bonds and Loans | 4,664.2 | +6.9% |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 4.6% (Actual Exchange Rate) driven by favorable foreign exchange rates and growth in GI, Rare Diseases, and PDT Immunology. This offset declines in Oncology and Neuroscience due to generic erosion and competition.
- Profit Decline: Operating profit fell 44.2% primarily due to JPY 119.3 billion in impairment losses (including JPY 74.0 billion for ALOFISEL and JPY 28.5 billion for EXKIVITY) and increased R&D and SG&A expenses.
- Tax Benefit: Net profit was supported by a JPY 46.9 billion income tax benefit, largely due to a JPY 63.5 billion reduction in tax expenses from the settlement of an Irish tax assessment regarding the Shire acquisition break fee.
- Product Performance:
- GI: ENTYVIO sales grew 13.0% (AER); DEXILANT declined 34.5% due to loss of exclusivity.
- Rare Diseases: TAKHZYRO grew 16.7%; FEIBA declined 11.3% due to competition.
- PDT Immunology: Immunoglobulin sales grew 24.4% driven by strong global demand.
- Oncology: VELCADE sales dropped 83.3% due to generic erosion; ADCETRIS grew 28.1%.
- Neuroscience: VYVANSE sales declined 6.7% due to generic entry in the U.S.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted strong momentum in growth and launch products, which contributed JPY 1,384.7 billion in revenue (+18.5% AER). Core Operating Profit decreased 9.3% AER due to product mix changes and pipeline investments. The company continues to invest in R&D (JPY 534.1 billion) across Innovative Biopharma, PDT, and Vaccines.
Risks and Contingencies:
- Legal Settlements: Takeda agreed to pay USD 506 million (including interest) to AbbVie regarding a supply agreement breach, with payment due in April 2024. An additional JPY 25.3 billion loss was recorded in the current period.
- Product Withdrawals: The company initiated a voluntary global withdrawal of EXKIVITY following the failure of the Phase 3 EXCLAIM-2 trial to meet its primary endpoint.
- Regulatory: The U.S. BLA for the dengue vaccine QDENGA was voluntarily withdrawn for further evaluation, though WHO recommendations for use in endemic areas were received.
Key Facts for Investor Verification
- Impairment Impact: Verify the long-term impact of the JPY 119.3 billion impairment charges on future R&D pipelines, specifically regarding ALOFISEL and EXKIVITY.
- AbbVie Litigation: Confirm the cash outflow timing and total liability associated with the USD 506 million AbbVie settlement due in April 2024.
- Generic Erosion: Monitor the trajectory of VYVANSE and DEXILANT sales as generic competition intensifies in the U.S. market.
- Cash Position: Assess liquidity given the 58% year-over-year decline in cash and cash equivalents to JPY 288.4 billion, driven by investing activities and commercial paper issuances.
- QDENGA Strategy: Track the status of the QDENGA vaccine application in the U.S. following the voluntary withdrawal of the BLA.